Edition:
India

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

12.77USD
23 Aug 2019
Change (% chg)

$-0.28 (-2.15%)
Prev Close
$13.05
Open
$12.96
Day's High
$13.29
Day's Low
$12.72
Volume
146,516
Avg. Vol
148,856
52-wk High
$17.96
52-wk Low
$9.40

Latest Key Developments (Source: Significant Developments)

Dicerna Says Enrollment Underway In PHYOX2 Trial Of DCR-PHXC
Friday, 21 Jun 2019 

June 21 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ PRESENTS ADDITIONAL DATA FROM PHYOX™1 STUDY OF DCR-PHXC IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1) AND TYPE 2 (PH2).DICERNA PHARMACEUTICALS INC - RESEARCHERS REPORT SUBSTANTIAL OXALATE REDUCTION FOLLOWING SINGLE-DOSE ADMINISTRATION OF DCR-PHXC IN ADDITIONAL PATIENTS WITH PH2.DICERNA PHARMACEUTICALS INC - ENROLLMENT UNDERWAY IN PIVOTAL PHYOX2 TRIAL OF DCR-PHXC.DICERNA PHARMACEUTICALS INC - DCR-PHXC WAS GENERALLY WELL-TOLERATED.DICERNA PHARMACEUTICALS - TO DATE, 4 SAES HAVE OCCURRED IN 3 PARTICIPANTS, NONE WERE DEEMED RELATED TO STUDY DRUG.DICERNA PHARMACEUTICALS INC - INVESTIGATORS OBSERVED NO CLINICALLY MEANINGFUL SAFETY SIGNALS INCLUDING FROM LIVER FUNCTION TESTS.DICERNA - EXPECT A MULTI-DOSE REGIMEN OF DCR-PHXC MAY OFFER POTENTIAL FOR MORE PRONOUNCED, SUSTAINED REDUCTIONS IN URINARY OXALATE.  Full Article

Dicerna Pharmaceuticals Inc posts Qtrly Loss Per Share $0.29
Tuesday, 12 Mar 2019 

March 11 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ REPORTS FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.DICERNA PHARMACEUTICALS INC - AS OF DECEMBER 31, 2018, DICERNA HAD $302.6 MILLION IN CASH, CASH EQUIVALENTS AND HELD-TO-MATURITY INVESTMENTS.DICERNA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.29.  Full Article

Lilly, Dicerna Announce RNAi Licensing, Research Collaboration
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Eli Lilly and Co LLY.N::ELI LILLY AND CO SAYS ANNOUNCE RNAI LICENSING AND RESEARCH COLLABORATION WITH DICERNA PHARMACEUTICALS.ELI LILLY - WILL UTILIZE DICERNA’S GALXC RNAI TECHNOLOGY PLATFORM TO PROGRESS NEW DRUG TARGETS TOWARD CLINICAL DEVELOPMENT, COMMERCIALIZATION.ELI LILLY - RESEARCH COLLABORATION FOCUSED ON POTENTIAL NEW MEDICINES IN AREAS OF CARDIO-METABOLIC DISEASE, NEURODEGENERATION AND PAIN.ELI LILLY - UNDER COLLABORATION TERMS, DICERNA TO RECEIVE UPFRONT PAYMENT OF $100 MILLION, AS WELL AS EQUITY INVESTMENT OF $100 MILLION AT A PREMIUM.ELI LILLY - DICERNA IS ELIGIBLE TO RECEIVE UP TO ABOUT $350 MILLION PER TARGET IN DEVELOPMENT AND COMMERCIALIZATION MILESTONES.ELI LILLY - DICERNA ALSO ELIGIBLE TO TIERED ROYALTIES RANGING FROM MID-SINGLE TO LOW-DOUBLE DIGITS ON PRODUCT SALES.ELI LILLY - DICERNA TO WORK EXCLUSIVELY WITH CO IN NEURODEGENERATION, PAIN FIELDS, AND ON SELECT TARGETS IN CARDIO-METABOLIC DISEASES.ELI LILLY - COS ANTICIPATE COLLABORATING ON MORE THAN TEN TARGETS.  Full Article

Dicerna Pharmaceuticals Inc Says Alexion May Terminate Collaboration Agreement At Any Time Without Cause
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Alexion Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC - ALEXION MAY TERMINATE COLLABORATION AGREEMENT AT ANY TIME WITHOUT CAUSE FOLLOWING A 90-DAY NOTICE PERIOD.DICERNA PHARMACEUTICALS-ALEXION COLLABORATION AGREEMENT ALSO PROVIDES FOR POTENTIAL ADDITIONAL PAYMENTS TO COMPANY OF UP TO $600.0 MILLION.  Full Article

Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock
Friday, 7 Sep 2018 

Sept 6 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK.DICERNA PHARMACEUTICALS- PRICING OF ITS UNDERWRITTEN REGISTERED PUBLIC OFFERING OF 7.7 MILLION SHARES OF ITS COMMON STOCK AT $13.02/SHARE.  Full Article

Dicerna Announces Proposed Follow-On Public Offering Of 6.15 Mln Common Stock
Thursday, 6 Sep 2018 

Sept 5 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PROPOSED FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 6.15 MILLION COMMON SHARES.INTENDS TO USE NET PROCEEDS FROM THIS OFFERING FOR PRECLINICAL STUDIES AND CLINICAL TRIALS.  Full Article

Dicerna Announces Proof Of Concept For Dcr-Phxc In The Treatment Of Primary Hyperoxaluria
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PROOF OF CONCEPT FOR DCR-PHXC IN THE TREATMENT OF PRIMARY HYPEROXALURIA.DICERNA PHARMACEUTICALS - INITIAL 6-WEEK DATA IN PHYOX PHASE 1 TRIAL SHOW SIGNIFICANT, SUSTAINED REDUCTION IN URINARY OXALATE LEVELS.DICERNA PHARMACEUTICALS INC - ALL ASSESSED PATIENTS IN TRIAL ARE ADULTS AND INCLUDE SEVEN PATIENTS WITH PH1 AND ONE PATIENT WITH PH2.DICERNA PHARMACEUTICALS INC - INTENDS TO PRESENT A DETAILED DATA READOUT FROM PHYOX TRIAL IN Q4 OF 2018.DICERNA PHARMACEUTICALS INC - PLANS TO INITIATE A REGISTRATION TRIAL FOR DCR-PHXC PENDING REGULATORY FEEDBACK IN Q1 OF 2019.  Full Article

Dicerna Pharmaceuticals Inc - QTRLY Loss Per Share $0.68
Thursday, 9 Aug 2018 

Dicerna Pharmaceuticals Inc ::DICERNA REPORTS SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.DICERNA PHARMACEUTICALS INC - AS OF JUNE 30, 2018, CO HAD $82.3 MILLION IN CASH AND CASH EQUIVALENTS.DICERNA PHARMACEUTICALS INC - BELIEVES IT HAS SUFFICIENT CASH TO FUND EXECUTION OF ITS CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019.DICERNA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.68.  Full Article

Dicerna Pharmaceuticals Files For Mixed Shelf Of Upto $250 Mln - SEC Filing
Thursday, 17 May 2018 

May 17 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING.  Full Article

Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals
Friday, 20 Apr 2018 

April 20 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION.ALNYLAM PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, DICERNA WILL PAY $25 MILLION COMPRISED OF CASH AND STOCK TO ALNYLAM.ALNYLAM PHARMACEUTICALS INC - SETTLEMENT DOES NOT INCLUDE ANY LICENSE TO ALNYLAM'S GALNAC CONJUGATE INTELLECTUAL PROPERTY.ALNYLAM - AS PER SETTLEMENT, DICERNA WILL BE RESTRICTED IN ITS DEVELOPMENT RELATING TO OLIGONUCLEOTIDE-BASED THERAPEUTICS FOR A DEFINED SET OF CO'S TARGETS.ALNYLAM PHARMACEUTICALS - ALL OTHER SETTLEMENT TERMS ARE CONFIDENTIAL.  Full Article